Maganin ciwon hanta, tsarin maganin ciwon hanta, Hanyar maganin ciwon hanta, hanyar maganin ciwon hanta, maganin ciwon hanta.
Cutar kansa ta hanta
Ciwon daji na hanta na farko na daya daga cikin abubuwan da ke haifar da munanan ciwace-ciwacen daji da ciwace-ciwace a kasashe masu tasowa, wadanda ke matukar barazana ga rayuwar mutane da lafiyarsu. Daidaita ganewar asali da maganin ciwon hanta yana da matukar muhimmanci don inganta ganewar asali da kuma kula da masu ciwon hanta da kuma inganta rayuwar marasa lafiya.
There are many treatment options for ciwon daji, including surgery, radiotherapy, radiofrequency ablation, venous embolization, and drug treatment. Among them, the chemotherapy effect of liver cancer is not good, because most liver cancer cells are not sensitive to chemotherapeutic drugs, even if the benefit of using chemotherapeutic drugs may be smaller than the side effects. Therefore, the proportion of patients with liver cancer treated with chemotherapy is not large.
Tun daga shekara ta 2007, zuwan sorafenib, magani na farko da aka yi niyya don ciwon hanta, ya karya yanayin cewa babu wani magani don ciwon hanta, amma ya ci gaba fiye da shekaru 10. Sorafenib ne kawai za a iya amfani dashi azaman magani na farko don ciwon daji na hanta wanda ba a iya gano shi ba. Bayan juriya na miyagun ƙwayoyi, ba ku san yadda za ku zaɓa ba?
However, through unremitting efforts, scientists broke through obstacles. In 2018, the second targeted drug that could replace sorafenib was successfully launched, that is, lovatinib! Both sorafenib and lovatinib It is a targeted drug used for first-line treatment of liver cancer. Later, a variety of second-line treatment drugs have also come out one after another!
Since 2017, many new high-level evidences in line with the principles of evidence-based medicine have emerged in the diagnosis, staging and treatment of liver cancer at home and abroad, especially research results adapted to China’s national conditions. This article focuses on the drug treatment plan and sequence in the latest edition of the “Specifications for the Diagnosis and Treatment of Primary Liver Cancer (2019 Edition)”, giving a clear guide for liver cancer friends.
Jagororin maganin ciwon hanta na FDA
ga abokan ciwon hanta.
| date | FDA ta amince da maganin ƙwayar cutar hanta | Bayyanawa | Yarda da gida |
| 2007-11 | Sorafenib (Sorafenib, Nexavar) | Don maganin cututtukan hanta da hanta | Inshorar likita ta jera kuma ta rufe ta |
| 2018-8 | Lenvatinib (Levatinib, Lenvima) | Don maganin layin farko na cututtukan hanta da ba shi da magani | Jerin gida |
| 2017-4 | Regorafenib (Sigvarga) | Jiyya ta biyu don cutar kansar hanta mai kama da sorafenib | Kasuwar cikin gida |
| 2017-9 | Nivolumab (navumab, Opdivo) | Jiyya ta biyu don cutar kansar hanta mai kama da sorafenib | Kasuwar cikin gida |
Zaɓin maganin layin farko don cutar hanta
(1) Sorafenib
Yawancin bincike na asibiti sun nuna cewa Sorafenib yana da wasu fa'idodin rayuwa ga marasa lafiya da ciwon hanta mai ci gaba a cikin ƙasashe daban-daban da kuma baya tare da cututtukan hanta daban-daban (matakin shaida 1).
Abunda aka saba amfani dashi shine MG 400 a baki, sau biyu a rana. Ana iya amfani dashi don Yara-Pugh Class A ko B tare da aikin hanta. Idan aka kwatanta da aikin hanta na Yara-Pugh B, Child-Pugh A amfanin rayuwar marasa lafiya ya fi bayyana.
Kuna buƙatar kulawa da tasiri akan HBV da aikin hanta, da inganta haɓaka cutar hanta ta asali a cikin aikin. Mafi munin halayen rashin lafiya shine gudawa, raunin nauyi, ciwon hannu da ƙafa, kurji, myocardial ischemia, da hauhawar jini, wanda yawanci ke faruwa tsakanin makonni 2 zuwa 6 bayan fara magani.
(2) Lemvatinib
Lenvatinib ya dace da marasa lafiyan da basu da matsala da mataki na IIb, IIIa, IIIb, aikin hanta Child-Pugh A ciwon hanta na hanta, kuma maganin sa na farko baya ƙasa da sorafenib. Ciwon hanta mai alaƙa da HBV yana da mafi alfanun Tsira [185] (matakin shaidar 1).
An amince da Lenvatinib don amfani dashi a cikin Yara-Pugh A masu fama da cutar kansar hanta tare da ci gaba da ciwon hanta. Amfani: 12mg, na baka, sau ɗaya kowace rana don nauyin jiki ≥60kg; 8mg, na baka, sau daya a rana domin nauyin jiki <60kg. Matsalolin illa na yau da kullun sune hauhawar jini, gudawa, rage ci, gajiya, ciwon ƙafa, ƙashin furotin, tashin zuciya, da hypothyroidism.
(3) Ciwon sankarar magani
An amince da yarjejeniyar FOLFOX4 (fluorouracil, calcium folinate, oxaliplatin). Kasar Sin don maganin ci gaba na gida da hanta ciwon daji wanda bai dace da aikin tiyata ba ko magani na gida (matakin shaida 1).
Yawancin karatun lokaci na II sunyi rahoton cewa ilimin kimiya tare da oxaliplatin haɗe tare da sorafenib na iya haɓaka ƙimar amsawa na haƙiƙa, faɗaɗa rayuwa mara ci gaba da rayuwa gabaɗaya, da samar da aminci mai kyau (matakin shaida 3).
Ga marasa lafiya da ke da aiki mai kyau na hanta da yanayin jiki, ana iya yin la'akari da wannan haɗin haɗin gwiwa, amma har yanzu ana buƙatar nazarin binciken bazuwar asibiti don samar da babbar shaidar shaidar likita. Kari akan haka, arsenic trioxide yana da wani sakamako na magance cutar kansar hanta mai ci gaba (matakin shaidar 3). A aikace-aikacen asibiti, ya kamata a kula don saka idanu da kuma hana cutar hanta da koda.
Layi na biyu na maganin cutar hanta
(1) Regoni
An yarda Regorafenib don amfani a cikin marasa lafiya tare da mataki na IIb, IIIa, da IIIb ciwon daji na hanta na CNLC waɗanda aka taɓa bi da su tare da sorafenib (matakin shaida na 1). Amfani shine 160mg sau ɗaya kowace rana don sati 3 kuma an dakatar dashi na sati 1.
A China, matakin farko zai iya zama 80mg ko 120mg sau ɗaya, sau ɗaya a rana, kuma a hankali ya karu bisa ga haƙuri da haƙuri. Abubuwa masu illa na yau da kullun sune hauhawar jini, halayen fata na ƙafa-ƙafa, gajiya, da gudawa.
(2) Navumab da Paimumab
FDA ta Amurka ta amince da amfani da Navulinu monoclonal antibodies (Nivolumab) da Pabrolizumab monoclonal antibodies (Pembrolizumab) a cikin marasa lafiya da ciwon hanta da suka ci gaba ko ba za su iya jure wa sorafenib ba bayan maganin sorafenib na baya (matakin shaida 2).
A halin yanzu, magungunan rigakafin rigakafi da kamfanonin kasar Sin suka samar da kansu, kamar su Carellidizum monoclonal antibodies, Treplepril monoclonal antibodies, da Xindili monoclonal antibodies, suna gudanar da bincike na asibiti. Haɗin kai immunotherapy and targeted drugs, chemotherapeutic drugs, and topical treatments is also constantly being explored.
Sauran immunomodulators (kamar interferon α, thymosin α1, da sauransu), immunotherapy na salula (kamar su. chimeric antigen receptor T cell far, CAR-T, da cytokine-induced killer cell far, CIK) duk suna da wasu tasirin antitumor. Duk da haka, har yanzu ba a tabbatar da shi ta manyan binciken asibiti ba.
